PDF herunterladen
Semin Liver Dis 2024; 44(01): 023-034
DOI: 10.1055/s-0043-1778127
Review Article

Algorithms for Early Detection of Silent Liver Fibrosis in the Primary Care Setting

Katrine Tholstrup Bech 
1   Department of Gastroenterology and Hepatology, Odense University Hospital, Odense C, Denmark
2   Institute of Clinical Research, University of Southern Denmark, Odense C, Denmark
,
Katrine Prier Lindvig 
1   Department of Gastroenterology and Hepatology, Odense University Hospital, Odense C, Denmark
2   Institute of Clinical Research, University of Southern Denmark, Odense C, Denmark
,
Maja Thiele 
1   Department of Gastroenterology and Hepatology, Odense University Hospital, Odense C, Denmark
2   Institute of Clinical Research, University of Southern Denmark, Odense C, Denmark
,
Laurent Castera 
3   Service d'Hépatologie, Assistance Publique-Hôpitaux de Paris (APHP), Hôpital Beaujon, Clichy, France
4   Faculté de Médecine, Université Paris Cité, UMR1149 (CRI), INSERM, Paris, France
› Institutsangaben Funding K.T.B., K.P.L., M.T., and L.C. are funded by a grant from the European Union's Horizon 2020 research and innovation program (LiverScreen, grant number 847989). K.T.B., K.P.L., and M.T. are funded by a grant from the Novo Nordisk Foundation (DECIDE, grant number NNF20OC0059393). K.P.L. is funded by a grant from the European Union's EuroStars program (grant number E83).
› Weitere Informationen
    Lizenzen und Reprints


Abstract

More than one-third of the adult world population has steatotic liver disease (SLD), with a few percent of individuals developing cirrhosis after decades of silent liver fibrosis accumulation. Lack of systematic early detection causes most patients to be diagnosed late, after decompensation, when treatment has limited effect and survival is poor. Unfortunately, no isolated screening test in primary care can sufficiently predict advanced fibrosis from SLD. Recent efforts, therefore, combine several parameters into screening algorithms, to increase diagnostic accuracy. Besides patient selection, for example, by specific characteristics, algorithms include nonpatented or patented blood tests and liver stiffness measurements using elastography-based techniques. Algorithms can be composed as a set of sequential tests, as recommended by most guidelines on primary care pathways. Future use of algorithms that are easy to interpret, cheap, and semiautomatic will improve the management of patients with SLD, to the benefit of global health care systems.

Keywords

artificial intelligence - fibroScan - NAFLD - alcohol-related liver disease - noninvasive tests


Publikationsverlauf

Artikel online veröffentlicht:
23. Januar 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Huang DQ, Terrault NA, Tacke F. et al. Global epidemiology of cirrhosis—aetiology, trends and predictions. Nat Rev Gastroenterol Hepatol 2023; 20 (06) 388-398 DOI: 10.1038/s41575-023-00759-2.
    CrossrefPubMedGoogle Scholar
  • 2 Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol 2023; 79 (02) 516-537
    CrossrefPubMedGoogle Scholar
  • 3 Ginès P, Castera L, Lammert F. et al; LiverScreen Consortium Investigators. Population screening for liver fibrosis: toward early diagnosis and intervention for chronic liver diseases. Hepatology 2022; 75 (01) 219-228
    CrossrefPubMedGoogle Scholar
  • 4 Karlsen TH, Sheron N, Zelber-Sagi S. et al. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet 2022; 399 (10319): 61-116
    CrossrefPubMedGoogle Scholar
  • 5 Rinella ME, Lazarus JV, Ratziu V. et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 2023; 79 (06) 1542-1556
    CrossrefPubMedGoogle Scholar
  • 6 Wilson JMG, Jungner YG. [Principles and practice of mass screening for disease]. Bol Oficina Sanit Panam 1968; 65 (04) 281-393
    PubMedGoogle Scholar
  • 7 Udell JA, Wang CS, Tinmouth J. et al. Does this patient with liver disease have cirrhosis?. JAMA 2012; 307 (08) 832-842
    CrossrefPubMedGoogle Scholar
  • 8 Lindvig KP, Hansen TL, Madsen BS. et al. Diagnostic accuracy of routine liver function tests to identify patients with significant and advanced alcohol-related liver fibrosis. Scand J Gastroenterol 2021; 56 (09) 1088-1095
    CrossrefPubMedGoogle Scholar
  • 9 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, Clinical Practice Guideline Panel, Chair, EASL Governing Board representative, Panel members. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol 2021; 75 (03) 659-689
    CrossrefPubMedGoogle Scholar
  • 10 Rinella ME, Neuschwander-Tetri BA, Siddiqui MS. et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 2023; 77 (05) 1797-1835
    CrossrefPubMedGoogle Scholar
  • 11 Kanwal F, Shubrook JH, Adams LA. et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology 2021; 161 (05) 1657-1669
    CrossrefPubMedGoogle Scholar
  • 12 Cusi K, Isaacs S, Barb D. et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract 2022; 28 (05) 528-562
    CrossrefPubMedGoogle Scholar
  • 13 Canivet CM, Costentin C, Irvine KM. et al. Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD. Hepatology 2023; 77 (03) 920-930
    CrossrefPubMedGoogle Scholar
  • 14 Lazarus JV, Mark HE, Anstee QM. et al; NAFLD Consensus Consortium. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol 2022; 19 (01) 60-78
    CrossrefPubMedGoogle Scholar
  • 15 Blais P, Husain N, Kramer JR, Kowalkowski M, El-Serag H, Kanwal F. Nonalcoholic fatty liver disease is underrecognized in the primary care setting. Am J Gastroenterol 2015; 110 (01) 10-14
    CrossrefPubMedGoogle Scholar
  • 16 Castera L, Laouenan C, Vallet-Pichard A. et al; QUID-NASH investigators. High prevalence of NASH and advanced fibrosis in type 2 diabetes: a prospective study of 330 outpatients undergoing liver biopsies for elevated ALT, using a low threshold. Diabetes Care 2023; 46 (07) 1354-1362
    CrossrefPubMedGoogle Scholar
  • 17 Lindvig KP, Wernberg CW, Kjaergaard M. et al. Only one-third of referrals for fatty liver disease are on time: real-world study reveals opportunities to avoid unnecessary and delayed referrals. Scand J Gastroenterol 2022; 57 (12) 1478-1485
    CrossrefPubMedGoogle Scholar
  • 18 Younossi ZM, Ong JP, Takahashi H. et al; Global Nonalcoholic Steatohepatitis Council. A global survey of physicians knowledge about nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2022; 20 (06) e1456-e1468
    CrossrefPubMedGoogle Scholar
  • 19 Patel PJ, Banh X, Horsfall LU. et al. Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis. Intern Med J 2018; 48 (02) 144-151
    CrossrefPubMedGoogle Scholar
  • 20 Canivet CM, Smati S, Lannes A. et al. Awareness of chronic liver diseases, a comparison between diabetologists and general practitioners. Clin Res Hepatol Gastroenterol 2022; 46 (04) 101848
    CrossrefPubMedGoogle Scholar
  • 21 Askgaard G, Kjær MS, Tolstrup JS. Opportunities to prevent alcoholic liver cirrhosis in high-risk populations: a systematic review with meta-analysis. Am J Gastroenterol 2019; 114 (02) 221-232
    CrossrefPubMedGoogle Scholar
  • 22 O'Sullivan JW, Stevens S, Hobbs FDR. et al. Temporal trends in use of tests in UK primary care, 2000-15: retrospective analysis of 250 million tests. BMJ 2018; 363: k4666
    CrossrefPubMedGoogle Scholar
  • 23 Castera L, Boursier J. Noninvasive algorithms for the case finding of “at-risk” patients with NAFLD. Semin Liver Dis 2022; 42 (03) 313-326
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 24 Lackner C, Spindelboeck W, Haybaeck J. et al. Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease. J Hepatol 2017; 66 (03) 610-618
    CrossrefPubMedGoogle Scholar
  • 25 Rasmussen DN, Thiele M, Johansen S. et al; GALAXY, MicrobLiver consortia. Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease. J Hepatol 2021; 75 (05) 1017-1025
    CrossrefPubMedGoogle Scholar
  • 26 Sanyal AJ, Van Natta ML, Clark J. et al; NASH Clinical Research Network (CRN). Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med 2021; 385 (17) 1559-1569
    CrossrefPubMedGoogle Scholar
  • 27 Taylor RS, Taylor RJ, Bayliss S. et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology 2020; 158 (06) 1611-1625.e12
    CrossrefPubMedGoogle Scholar
  • 28 Bours MJL. Bayes' rule in diagnosis. J Clin Epidemiol 2021; 131: 158-160
    CrossrefPubMedGoogle Scholar
  • 29 Åberg F, Jula A, Färkkilä M. et al. Comparison of various strategies to define the optimal target population for liver fibrosis screening: a population-based cohort study. United European Gastroenterol J 2022; 10 (09) 1020-1028
    CrossrefPubMedGoogle Scholar
  • 30 Dillon JF, Miller MH, Robinson EM. et al. Intelligent liver function testing (iLFT): a trial of automated diagnosis and staging of liver disease in primary care. J Hepatol 2019; 71 (04) 699-706
    CrossrefPubMedGoogle Scholar
  • 31 Zhang X, Yip TC, Wong GL. et al. Clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated fibrosis score calculation and electronic reminder messages: a randomised controlled trial. Gut 2023; 72 (12) 2364-2371
    CrossrefPubMedGoogle Scholar
  • 32 Anstee QM, Castera L, Loomba R. Impact of non-invasive biomarkers on hepatology practice: Past, present and future. J Hepatol 2022; 76 (06) 1362-1378
    CrossrefPubMedGoogle Scholar
  • 33 Thiele M, Johansen S, Israelsen M. et al; MicrobPredict, LiverScreen, LiverHope and GALAXY Consortia. Non-invasive assessment of hepatic decompensation. Hepatology 2023; DOI: 10.1097/HEP.0000000000000618.
    CrossrefPubMedGoogle Scholar
  • 34 Ginès P, Thiele M, Graupera I. et al. Screening for fibrosis to diagnose liver diseases early: the LIVERSCREEN project. Nat Med 2023; 29 (04) 774-775
    CrossrefPubMedGoogle Scholar
  • 35 Serra-Burriel M, Graupera I, Torán P. et al; Investigators of the LiverScreen Consortium. Transient elastography for screening of liver fibrosis: cost-effectiveness analysis from six prospective cohorts in Europe and Asia. J Hepatol 2019; 71 (06) 1141-1151
    CrossrefPubMedGoogle Scholar
  • 36 Asphaug L, Thiele M, Krag A, Melberg HO. Cost-effectiveness of non-invasive screening for alcohol-related liver fibrosis. Hepatology 2020; 71 (06) 2093-2104
    CrossrefPubMedGoogle Scholar
  • 37 Sanyal AJ, Castéra L, Wong VW. Noninvasive assessment of liver fibrosis in NAFLD. Clin Gastroenterol Hepatol 2023; 21 (08) 2026-2039
    CrossrefPubMedGoogle Scholar
  • 38 Mahady SE, Macaskill P, Craig JC. et al. Diagnostic accuracy of noninvasive fibrosis scores in a population of individuals with a low prevalence of fibrosis. Clin Gastroenterol Hepatol 2017; 15 (09) 1453-1460.e1
    CrossrefPubMedGoogle Scholar
  • 39 Hagström H, Talbäck M, Andreasson A, Walldius G, Hammar N. Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease. J Hepatol 2020; 73 (05) 1023-1029
    CrossrefPubMedGoogle Scholar
  • 40 Boursier J, Hagström H, Ekstedt M. et al. Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events. J Hepatol 2022; 76 (05) 1013-1020
    CrossrefPubMedGoogle Scholar
  • 41 Graupera I, Thiele M, Serra-Burriel M. et al; Investigators of the LiverScreen Consortium. Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population. Clin Gastroenterol Hepatol 2022; 20 (11) 2567-2576.e6
    CrossrefPubMedGoogle Scholar
  • 42 Kjaergaard M, Lindvig KP, Thorhauge KH. et al. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease. J Hepatol 2023; 79 (02) 277-286
    CrossrefPubMedGoogle Scholar
  • 43 Lee J, Vali Y, Boursier J. et al. Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: a systematic review. Liver Int 2021; 41 (02) 261-270
    CrossrefPubMedGoogle Scholar
  • 44 Colom R, Karama S, Jung RE, Haier RJ. Human intelligence and brain networks. Dialogues Clin Neurosci 2010; 12 (04) 489-501
    CrossrefPubMedGoogle Scholar
  • 45 Rajkomar A, Dean J, Kohane I. Machine learning in medicine. N Engl J Med 2019; 380 (14) 1347-1358
    CrossrefPubMedGoogle Scholar
  • 46 Ahn JC, Connell A, Simonetto DA, Hughes C, Shah VH. Application of artificial intelligence for the diagnosis and treatment of liver diseases. Hepatology 2021; 73 (06) 2546-2563
    CrossrefPubMedGoogle Scholar
  • 47 Serra-Burriel M, Juanola A, Serra-Burriel F. et al; LiverScreen Consortium Investigators. Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study. Lancet 2023; 402 (10406): 988-996
    CrossrefPubMedGoogle Scholar
  • 48 Blanes-Vidal V, Lindvig KP, Thiele M, Nadimi ES, Krag A. Artificial intelligence outperforms standard blood-based scores in identifying liver fibrosis patients in primary care. Sci Rep 2022; 12 (01) 2914
    CrossrefPubMedGoogle Scholar
  • 49 Chang D, Truong E, Mena EA. et al. Machine learning models are superior to noninvasive tests in identifying clinically significant stages of NAFLD and NAFLD-related cirrhosis. Hepatology 2023; 77 (02) 546-557
    CrossrefPubMedGoogle Scholar
  • 50 Sripongpun P, Kim WR, Mannalithara A. et al. The steatosis-associated fibrosis estimator (SAFE) score: a tool to detect low-risk NAFLD in primary care. Hepatology 2023; 77 (01) 256-267
    CrossrefPubMedGoogle Scholar
  • 51 Yip TC, Ma AJ, Wong VW. et al. Laboratory parameter-based machine learning model for excluding non-alcoholic fatty liver disease (NAFLD) in the general population. Aliment Pharmacol Ther 2017; 46 (04) 447-456
    CrossrefPubMedGoogle Scholar
  • 52 Otero Sanchez L, Zhan CY, Gomes da Silveira Cauduro C. et al. A machine learning-based classification of adult-onset diabetes identifies patients at risk of liver-related complications. JHEP Rep Innov Hepatol 2023; 5 (08) 100791
    CrossrefPubMedGoogle Scholar
  • 53 Niu L, Thiele M, Geyer PE. et al. Noninvasive proteomic biomarkers for alcohol-related liver disease. Nat Med 2022; 28 (06) 1277-1287
    CrossrefPubMedGoogle Scholar
  • 54 Schomerus G, Leonhard A, Manthey J. et al. The stigma of alcohol-related liver disease and its impact on healthcare. J Hepatol 2022; 77 (02) 516-524
    CrossrefPubMedGoogle Scholar
  • 55 Tavaglione F, Jamialahmadi O, De Vincentis A. et al. Development and validation of a score for fibrotic nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2023; 21 (06) 1523-1532.e1
    CrossrefPubMedGoogle Scholar
  • 56 Coste P, Llop E, Perelló C. et al. Comparison of non-invasive fibrosis scores to predict increased liver stiffness in the general population with unknown liver disease: Searching for the primary physician's best friend. Dig Liver Dis 2022; 54 (09) 1209-1214
    CrossrefPubMedGoogle Scholar
  • 57 Labenz C, Arslanow A, Nguyen-Tat M. et al. Structured Early detection of Asymptomatic Liver Cirrhosis: Results of the population-based liver screening program SEAL. J Hepatol 2022; 77 (03) 695-701
    CrossrefPubMedGoogle Scholar
  • 58 Åberg F, Luukkonen PK, But A. et al. Development and validation of a model to predict incident chronic liver disease in the general population: The CLivD score. J Hepatol 2022; 77 (02) 302-311
    CrossrefPubMedGoogle Scholar
  • 59 Eslam M, Wong GL, Hashem AM. et al. A sequential algorithm combining ADAPT and liver stiffness can stage metabolic-associated fatty liver disease in hospital-based and primary care patients. Am J Gastroenterol 2021; 116 (05) 984-993
    CrossrefPubMedGoogle Scholar
  • 60 Fowell AJ, Fancey K, Gamble K. et al. Evaluation of a primary to secondary care referral pathway and novel nurse-led one-stop clinic for patients with suspected non-alcoholic fatty liver disease. Frontline Gastroenterol 2020; 12 (02) 102-107
    CrossrefPubMedGoogle Scholar
  • 61 Hydes T, Moore M, Stuart B. et al. Can routine blood tests be modelled to detect advanced liver disease in the community: model derivation and validation using UK primary and secondary care data. BMJ Open 2021; 11 (02) e044952
    CrossrefPubMedGoogle Scholar
  • 62 Younossi ZM, Pham H, Felix S. et al. Identification of high-risk patients with nonalcoholic fatty liver disease using noninvasive tests from primary care and endocrinology real-world practices. Clin Transl Gastroenterol 2021; 12 (04) e00340
    CrossrefPubMedGoogle Scholar
  • 63 Chalmers J, Wilkes E, Harris R. et al. The development and implementation of a commissioned pathway for the identification and stratification of liver disease in the community. Frontline Gastroenterol 2020; 11 (02) 86-92
    CrossrefPubMedGoogle Scholar
  • 64 Shaheen AA, Riazi K, Medellin A. et al. Risk stratification of patients with nonalcoholic fatty liver disease using a case identification pathway in primary care: a cross-sectional study. CMAJ Open 2020; 8 (02) E370-E376
    CrossrefPubMedGoogle Scholar
  • 65 Srivastava A, Gailer R, Tanwar S. et al. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. J Hepatol 2019; 71 (02) 371-378
    CrossrefPubMedGoogle Scholar
  • 66 El-Gohary M, Moore M, Roderick P. et al. Local care and treatment of liver disease (LOCATE) - a cluster-randomized feasibility study to discover, assess and manage early liver disease in primary care. PLoS ONE 2018; 13 (12) e0208798
    CrossrefPubMedGoogle Scholar
  • 67 Harman DJ, Ryder SD, James MW. et al. Direct targeting of risk factors significantly increases the detection of liver cirrhosis in primary care: a cross-sectional diagnostic study utilising transient elastography. BMJ Open 2015; 5 (04) e007516
    CrossrefPubMedGoogle Scholar
  • 68 McLernon DJ, Donnan PT, Sullivan FM. et al. Prediction of liver disease in patients whose liver function tests have been checked in primary care: model development and validation using population-based observational cohorts. BMJ Open 2014; 4 (06) e004837
    CrossrefPubMedGoogle Scholar